Kidney Cancer Coverage from Every Angle

Brian I. Rini, MD, on Using Biomarkers to Inform Treatment Decisions in Renal Cell Carcinoma

Posted: Friday, April 16, 2021

Brian I. Rini, MD, of Vanderbilt University, discusses results from the IMmotion151 trial, analyzing tumors for RNA gene expression, and using biomarker analyses to identify subgroups of patients with renal cell carcinoma who are most likely to benefit from combined anti-VEGF plus anti–PD-L1/PD-1 therapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.